Systemic therapy for advanced or recurrent endometrial carcinoma.
The prognosis for metastatic or recurrent endometrial cancer remains poor. Patients with local recurrences can sometimes be salvaged with radiation, and these salvage rates might improve with the addition of concomitant chemotherapy. Hormone therapy benefits a small group of patients, and routine immunohistochemical determination of tumor receptor status may help select patients most likely to benefit from such therapy. Anthracyclines, platinum compounds, and paclitaxel consistently produce response rates of over 20%. Combination chemotherapy produces higher response rates, but it is toxic and appears to have minimal effect on survival. New drugs and combinations continue to be tested. A subset of endometrial cancers overexpress the HER2/neu oncogene, and a trial of anti-HER2/neu monoclonal antibody for this group is planned through the Gynecologic Oncology Group.
Fleming
G F
GF
Section of Hematology/Oncology, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 2115, Chicago, IL 60637-1470, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D016019:Survival Analysis
D000970:Antineoplastic Agents